During the PROTECT VIII main and extension studies

Target-joint resolution with Jivi®

Results from a post hoc analysis of target-joint status in 82 patients in the prophylactic group from baseline through the main study and into the extension period (median time of 1402 days [range: 297-1706]1)

Study Design Chart
Study Design Chart
  • Patients remaining on the same prophylaxis regimen during the last 90 days of treatment. Median (Q1; Q3) joint ABRs were 0.00 (0.0,8.1) for twice-weekly and 0.00 (0.0; 4.1) for every-5-day final on-study dosing interval.2
  • As defined by the International Society of Thrombosis and Hemostasis (ISTH).1